The global topiramate market is anticipated to grow at a significant CAGR during the forecast period. Topiramate is a medicine which is used for the treatment of epilepsy and is also referred to as anti-epileptic medicines. Antiepileptic drugs (AED) are generally used for neurologic and psychiatric purposes. The primary indication for this family of drugs is treating seizure disorders. Topiramate is only available on prescription and it can also be taken to prevent migraine. Increasing prevalence of epilepsy and migraine across the globe is expected to surge the demand for topiramate globally.
To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/topiramate-market
According to the World Health Organization (WHO) epilepsy is a chronic non-communicable disease of the brain that affects people of all ages. As of 2019, nearly 50 million people across the globe had epilepsy. This makes epilepsy one of the most common neurological diseases globally. Moreover, as per the WHO, it is also estimated that up to 70% of people living with epilepsy could live seizure-free if properly diagnosed and treated. The risk of premature mortalities in people with epilepsy is up to three times higher than general population. Growing number of migraine cases is also surging the demand for topiramate across the globe.
Some key players operating in the market include Aurobindo Pharma Ltd., Johnson & Johnson Services, Inc., and Pfizer Inc., among others. The market players are eyeing on strengthening their position in the market by adopting various strategies as mergers and acquisitions, partnerships, collaborations, new product launch and development in the existing product portfolio, and so on. For instance, in November 2021, Eton Pharmaceuticals Inc. and Azurity Pharmaceuticals, Inc. announced the US Food and Drug Administration (FDA) approval of EPRONTIA (topiramate) oral solution, 25mg/mL. EPRONTIA has been approved as a monotherapy for treatment of partial-onset or primary generalized tonic-clonic seizures in patients 2 years of age and older; an adjunctive therapy for treatment of partial-onset seizures, primary generalized tonic-clonic seizures or seizures associated with Lennox-Gastaut syndrome in patients 2 years of age and older; and as a preventive treatment of migraine in patients 12 years of age and older.
Market Coverage
- The market number available for – 2020-2027
- Base year- 2020
- Forecast period- 2021-2027
- Segment Covered-
o By Product
o By Application
- Regions covered-
o North America
o Europe
o Asia-Pacific
o Rest of the World
- Competitive Landscape: Aurobindo Pharma Ltd., Johnson & Johnson Services, Inc., and Pfizer Inc., among others.
Key questions addressed by the report
- What is the market growth rate?
- Which segment and region dominate the market in the base year?
- Which segment and region will project the fastest growth in the market?
- How COVID-19 impacted the market?
o Deviation from the pre-COVID-19 forecast
o Most affected region and segment
- Who is the leader in the market?
- How are players addressing challenges to sustain growth?
- Where is the investment opportunity?
Global Topiramate Market Report by Segment
By Product
- 0.98
- 0.99
- Others
By Application
- Anticonvulsant
- Antimigraine
- Others
A full report of Topiramate Market is available at: https://www.omrglobal.com/industry-reports/topiramate-market
Topiramate Market– Segment by Region
North America
- United States
- Canada
Europe
- Germany
- United Kingdom
- France
- Spain
- Italy
- Rest of Europe
Asia-Pacific
- China
- Japan
- India
- Rest of Asia-Pacific
Rest of the World
- Middle East & Africa
- Latin America
